NCT04858880招募中不适用
Personalized Radiotherapy for Biochemical Recurrence of Prostate Cancer After Prostatectomy: a Randomized Phase III Study.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 374
- 试验地点
- 6
- 主要终点
- Failure-free survival (FFS).
研究概览
简要总结
A randomized phase III trial to study the effect of adding lymph node irradiation in patients with poor prostate-specific antigen (PSA) response during salvage radiotherapy for biochemical recurrence (0.15 ≤ PSA <0.70 ng/ml) after prostatectomy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Life expectancy > 10 years
- •Age ≥18 years.
- •World Health Organization (WHO) performance status 0-
- •Estimated life expectancy >10 years.
- •Histological evidence of prostate cancer in the prostatectomy specimen
- •Primary tumor, regional nodes, metastasis (TNM): any primary tumor (pT), pathologically node-negative (pN0), M
- •Biochemical Recurrence (BCR) after prostatectomy, with 0.15 ≤ PSA <0.70 ng/ml.
- •Patients must be able to comply with the protocol.
- •Signed informed consent.
- •Adequate laboratory findings (Haemoglobin (Hb) >90g/L, absolute neutrophil count >1.0x109/L, platelets >75x109/l, bilirubin <1.5x upper limit of normal (ULN), alanine aminotransferase (ALAT) <5x ULN and creatinine <1.5 ULN).
排除标准
- •Metastases (regional lymph nodes or distant)* diagnosed with imaging.
- •Prior or ongoing hormonal therapy (antiandrogens or gonadotropin releasing hormone).
- •Prior radiotherapy to the pelvis.
- •Prior malignancy other than prostate cancer and basalioma in the past five years.
- •Clinically significant (i.e. active) cardiovascular disease e.g. myocardial infarction (≤6 months), unstable angina, New York Heart Association (NYHA) class III-IV congestive heart failure.
- •Severe pulmonary disease.
- •Any other serious or uncontrolled illness which in the opinion of the investigator makes it undesirable for the patient to enter the trial.
结局指标
主要结局
Failure-free survival (FFS).
时间窗: FFS after SRT, with failure defined as either biochemical or clinical recurrence (imaging or biopsy confirmed). FFS is calculated from the randomization date (arms A and B) until end of follow up (month 60 after
Failure-free survival after salvage radiotherapy (SRT), with failure defined as either biochemical, defined as verified PSA level of ≥ 0.2 ng/ml above the post-radiotherapy PSA nadir value or clinical Recurrence, imaging or biopsy confirmed.
次要结局
- Numbers of patients with acute toxicity (≤ 3 months after end of salvage radiotherapy).(Up to 3 months after end of salvage radiotherapy.)
- Systemic treatment-free survival.(Is evaluated from the randomization date (arms A and B) until end of follow up (month 60 after end of radiotherapy).)
- Prostate cancer specific survival.(Is evaluated from the randomization date (arms A and B) until end of follow up (month 60 after end of radiotherapy).)
- Overall survival.(Is evaluated from the randomization date (arms A and B) until end of follow up (month 60 after end of radiotherapy).)
- Numbers of patients with late toxicity (> 3 months to 5 years after end of salvage radiotherapy).(After 3 months after end of salvage therapy until end of follow up at month 60 after end of salvage therapy.)
- Distant metastasis-free survival.(Is evaluated from the randomization date (arms A and B) until end of follow up (month 60 after end of radiotherapy).)
- Patients self-esteem of quality of life.(Quality of life evaluated using questionnaire by the European Organisation for Research and Treatment of Cancer (EORTC), questionnaire is QLQ - PR25. Is done at baseline, at end of radiotherapy (43 days in Arm A, 35 days in Arm, month 12, 24, and 60.)
研究者
研究点 (6)
Loading locations...
相似试验
招募中
3 期
A Randomized Controlled Trial Evaluating of Prophylactic Irradiation in CRT for cT1bN0M0 ESCCEsophageal Squamous Cell CarcinomaNCT04328948National Cancer Center, Japan280
招募中
不适用
Novel Approach to Radiotherapy in Locally Advanced Lung Cancer Concomitant Navelbine®NSCLCNCT02354274Olfred Hansen330
招募中
3 期
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRTProstate CancerNCT05613023Institute of Cancer Research, United Kingdom1,128
终止
3 期
Conventional ADT w/ or w/Out Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADTProstate CancerNCT03777982Dana-Farber Cancer Institute12
招募中
不适用
Metastases Directed Therapy for Oligometastatic Breast CancerMetastatic CancerBreast CancerMetastatic Breast CancerNCT06144346National Cancer Institute, Egypt150